Evaluation of serum level of interleukin 17 in patients with ischemic heart disease referring to Afzalipour hospital in Kerman

Introduction:
Immunopathological and inflammatory processes play an important role in the onset and progression of ischemic heart disease. At the site of atherosclerotic plaques in coronary arteries, patients with ischemic heart disease have been shown to accumulate various cells such as monocyte, lymphocyte T and B cells, and PMN cells. The purpose of this study was to evaluate the serum level of interleukin 17 in patients with ischemic heart disease and its relation with disease risk factors.
.Material and method:
A total of 300 patients with IHD as having acute myocardial infarction (AMI; n = 100), stable angina (SA; n = 100) or unstable angina (UA; n = 100) and 100 healthy subjects as a control group were enrolled to study. Serum levels of Interleukin 17 were measured by ELISA and according to the guidelines of the relevant kit.
Finding:
Serum levels of Interleukin 17 are shown in Table 2 and Fig. 1. Serum levels of IL-17 in the AMI group in the SA group in the UA group and in the control group were 6.08 ± 1.12, 5.81 ± 1.05, 7.11 ± 1.37 and 3.46 ± 0.90 respectively. Statistical analysis showed that the difference between the different groups of patients with the control group was significant (P <0.01). There was no significant difference in serum level of interleukin 17 between groups of patients (P> 0.05). Serum interleukin 17 levels in diabetic patients were significantly higher than non-diabetic patients (P <0.03).
Conclusion:
This study showed that serum IL-17 level was associated with ischemic heart disease, and TH17 cells probably contribute to the pathogenesis of ischemic heart disease.